Myrtelle is a gene therapy company based in Wakefield, Massachusetts and founded in 2021 that develops therapeutics for myelin-based disorders. They are creating novel gene therapy vectors that can specifically target oligodendrocytes that produce myelin, with their programs focusing on rare CNS diseases such as Canavan disease and multiple system atrophy (MSA). Myrtelle uses a patient-centered, innovation-driven approach to benefit patients across the globe. Their research also attempts to better understand inheritance patterns of genetic diseases. Collaborations have been formed with Pfizer, Forge Biologics, and Dayton’s Children’s Hospital to improve their success. Overall, Myrtelle is committed to becoming the world leader in white matter disease gene therapies.

Myrtelle

Founded: 2020
Location: Wakefield, MA
Employee range: 1 - 10
Clinical stage: Clin1/Clin2
Therapy area: Canavan disease (ODD)
Drug types: GEN, PED, NEU, OTO
Lead product: Myr-101

Drug notes:

About:

Jobs: